Jonathan Hoggatt
Overview
Explore the profile of Jonathan Hoggatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoggatt J, Kfoury Y, Scadden D
Annu Rev Pathol
. 2016 May;
11:555-81.
PMID: 27193455
Regulation of stem cells in adult tissues is a key determinant of how well an organism can respond to the stresses of physiological challenge and disease. This is particularly true...
12.
Hoggatt J, Hoggatt A, Tate T, Fortman J, Pelus L
Exp Hematol
. 2015 Dec;
44(2):132-137.e1.
PMID: 26644183
The laboratory mouse is the model most frequently used in hematologic studies and assessment of blood parameters across a broad range of disciplines. Often, analysis of blood occurs in a...
13.
Hoggatt J, Tate T, Pelus L
Int J Nanomedicine
. 2015 Apr;
10:2647-52.
PMID: 25878498
Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative...
14.
Hoggatt J, Tate T, Pelus L
Methods Mol Biol
. 2014 Jul;
1185:43-64.
PMID: 25062621
Hematopoietic stem cell transplantation (HSCT) can be performed with hematopoietic stem and progenitor cells (HSPC) acquired directly from bone marrow, from umbilical cord blood or placental tissue, or from the...
15.
Speth J, Hoggatt J, Singh P, Pelus L
Blood
. 2013 Oct;
123(2):203-7.
PMID: 24167196
Hematopoietic stem cell (HSC) transplantation is a lifesaving therapy for a number of immunologic disorders. For effective transplant, HSCs must traffic from the peripheral blood to supportive bone marrow niches....
16.
Hoggatt J, Pelus L
Expert Opin Pharmacother
. 2013 Oct;
14(18):2453-6.
PMID: 24138174
For a number of malignant hematologic diseases, including leukemias, lymphomas and myelomas, hematopoietic stem cell transplantation remains the only curative option. The stem cell sources for these life-saving transplants come...
17.
Hoggatt J, Speth J, Pelus L
Stem Cells
. 2013 Oct;
31(12):2599-606.
PMID: 24123398
Hematopoietic stem cell transplantation is the only curative option for a number of malignant and nonmalignant diseases. As the use of hematopoietic transplant has expanded, so too has the source...
18.
Hoggatt J, Pelus L
Expert Opin Investig Drugs
. 2013 Oct;
23(1):21-35.
PMID: 24073859
Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and...
19.
Hoggatt J, Mohammad K, Singh P, Pelus L
Blood
. 2013 Sep;
122(17):2997-3000.
PMID: 24047650
Hematopoietic stem cell (HSC) transplantation is a lifesaving therapy for malignant and nonmalignant hematologic diseases and metabolic disorders. Although successful, hematopoietic transplantation can be hindered by inadequate stem cell number...
20.
Cutler C, Multani P, Robbins D, Kim H, Le T, Hoggatt J, et al.
Blood
. 2013 Sep;
122(17):3074-81.
PMID: 23996087
Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid availability and less stringent requirements for...